Skin patch study for a sedative medicine
This study tests a new skin patch that delivers a medicine called dexmedetomidine, which is normally used for sedation, to see how safe it is when applied repeatedly. It is for healthy people and may help find a non-invasive way to give this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must not have smoked or used nicotine products in the last 6 months.
- You need to weigh at least 110 pounds (50 kg) and have a body mass index (BMI) between 18 and 38.
- The skin where the patch will be placed must be clear of rashes, eczema, scars, tattoos, or excessive hair.
- If you are a woman, you must not be pregnant or planning to become pregnant, and use effective birth control.
- If you are a man, you must use reliable birth control during the study and for 3 months after.
- You must be in general good health, with no major medical conditions like HIV, hepatitis, or a history of seizures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how safe and well-tolerated a skin patch is on the back. It is for adults with sensitive skin who want to help evaluate a new cosmetic product.
This study tests a skin patch that helps children relax before surgery. The patch contains a medicine that is absorbed through the skin to reduce anxiety, so the child may need less anesthesia.
This study tests whether a new skin patch, DM1001, is safe and how well the body tolerates it. It is for healthy adults who want to help find out if this patch could be used for future treatments.
This study tests a medication called dexmedetomidine to see how it affects sleep, heart rhythms, and certain blood markers in older adults. The goal is to understand how this drug impacts sleep quality and brain health.
This trial tests a skin patch that delivers a medicine called dexmedetomidine to help calm agitation in people with Alzheimer's disease. It might be an option for those living in a care facility who have had recent episodes of agitation.
This study explores how people recover after being given a common sedative called dexmedetomidine. It may help doctors better understand and manage recovery from sedation.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.